wax chartcheck - 500 Beiträge pro Seite

[waxweazle]

chartupdate AAPL + neuer chart Boeing
Zum Apfel

nach der letzten Analyse zu Apple ist der Kurs schön nach oben gelaufen und hat den ersten Zielbereich erreicht.

MACD bullish cross
Ausbruch aus dem Wedge ( Wolf wave )
Neue Targets siehe chart
52 week highs sind nicht weit weg.



Zu Boeing

Boeing hat eine schöne Konsolidierung hinter sich.
Aus dieser Konsolidierung konnten wir heute nach oben ausbrechen.
die 52 week highs sind nicht weit.

MACD bullish cross
Chartsignal: Neues 26-Wochen Hoch
Chartsignal: Neues 13-Wochen Hoch



Beste grüsse
waxweazle

[waxweazle]

Antwort auf Beitrag Nr.: 48.858.698 von waxweazle am 22.01.15 23:46:48

Euro + Boeing

Hallo liebe Trader

Ich seh den euro so. ( Zeitraum etwas längerfristig )
Ich habe einen Langzeitchart gewählt und siehe da, es gibt ein klares Ziel
bzw bringt etwas Licht ins Dunkle.
Natürlich könnte die Währung noch etwas übertreiben und wir sehen Pari.
Aber ich denke auf Monatschluss sollten wir dann über der Grünenlinie schliessen.
Denn sonst würde es sehr Düster aussehen.
Der kurs befindet sich in der Nähe des 76er retrace



Boeing

Nach dem Boeing nach oben ausgebrochen ist haben wir am Freitag
diesen Ausbruch fast exakt zurückgetestet.
MACD bullish
RSI hat noch Platz




zu Apple gibt es aktuell charttechnisch nichts neues.
Kommende Woche werden die Zahlen gemeldet.


Beste Grüsse
waxweazle

[waxweazle]

Antwort auf Beitrag Nr.: 48.880.265 von waxweazle am 25.01.15 21:35:14

chartupdate us stocks

chartupdate us stocks
Hallo liebe Trader,

Seit der Vorstellung meiner Charts zu Boeing und Apple sind die Aktien sehr schön nach oben gelaufen.
Mit den passenden Scheinchen dazu hat man gut verdienen können.

CHartupdate zu Boeing
Denke das wir hier jetzt dann am oberen Ende angekommen sind und erstmal Seitwärts bzw. korrigieren werden.
RSI ist im Überkauftenbereich.




AAPL der Apfel

Sollten wir bei Apple das 52 Wochenhoch brechen sind weiter Kursgewinne Richtung 125 + drin.
MACD bullish
RSI hat noch genügend Platz nach oben
Volumen zieht an.
Weitere news




Amazon habe ich schon länger auf der Watchlist.
Wir haben einen schönen 3 Fachboden ausgebildet.
heute super Zahlen.
Dieses Jahr sollten wir die 400$ überwinden
Abwärtsrend nach Börsenschluss gebrochen.




Reboundchance bei Alibaba

Target Grünerbereich.
heute haben wir einen Hammer gebildet ( Candle )
Gap könnte nächste Woche geschlossen werden.





Beste Grüsse und danke für die likes
waxweazle
Z

[waxweazle]

Antwort auf Beitrag Nr.: 48.937.580 von waxweazle am 30.01.15 18:22:02

update diesemal ohne charts

AAPL weiter bullish sieht sehr gut aus



Ford Ausbruch nach oben
zwischen 17 und 16.50$ ist noch ein offens Gap das geschlossen werden sollte.
Automobilaktien laufen gerade sehr gut. Absatzzahlen steigen
GM ist auch ausgebrochen heute +3.5% up
Ford sollte folgen



Qualcomm

heute mit sehr guten news:


Qualcomm Settles Chinese Antitrust Charges, Ups Guidance - Analyst Blog
Zacks
By Zacks Equity Research 46 minutes ago






Yesterday, Qualcomm Inc. (QCOM), the largest mobile chipset developer globally, reached an agreement with Chinese regulatory authority, National Development and Reform Commission (NDRC), settling the 15 month old antimonopoly charges against the company.
Related Stories


As a settlement, Qualcomm will pay a fine of $975 million together with several royalty concessions to Chinese handset developers. Meanwhile, the company’s management also raised its financial outlook for fiscal 2015.

The stock price Qualcomm, which has lost value of around 18% over the last ten months, was up nearly 4% yesterday, including normal market trading time and aftermarket trade.

The Penalty

Way back in Nov 2013, the NDRC had initiated a probe into Qualcomm’s monopolistic practices in China. Following that, the NDRC determined that the company is exercising monopolistic power in the country. In addition to paying a fine of $975 million, the company is also offering new licensing norms which can be classified into 4 broad categories, which are:

Firstly, Qualcomm will offer licenses to its current 3G and 4G essential Chinese patents separately from licenses to its other patents and it will provide patent lists during the negotiation process.

Secondly, the chipmaker has agreed to lower its licensing fees to 5% for 3G devices and 3.5% for 4G devices including tri-mode LTE-TDD devices that do not have CDMA or WCDMA for branded devices sold for use in China, using a royalty base of 65% of the net selling price of the device.
Related Quotes

GOOGL540.16+2.06%
MSFT42.60+0.57%
AAPL122.02+1.92%

Google Inc. Watchlist
540.16+10.88(+2.06%)
NASDAQ4:00 PM EST

Docker Popularity A Game-Changer For Cloud, Linux?
Investor's Business Daily q 13 mins ago
Google holds its next I/O developer conference on May 28th and 29th
Engadget q 19 mins ago

More

Thirdly, Qualcomm will give its existing licensees an opportunity to elect to take the new terms for sales of branded devices for use in China as of Jan 1, 2015.

Finally, Qualcomm will not condition the sale of baseband chips on the chip customer signing a license agreement with terms that the NDRC found to be unreasonable or on the chip customer not challenging unreasonable terms in its license agreement.

What Drove the Stock Price?

The Chinese wireless market is currently the major growth area for Qualcomm. All three Chinese wireless behemoths have ramped up the deployment of 4G LTE (either TDD or FDD format) in recent times. Qualcomm generates 74% of its revenues from chipset sale but earns 58% of its profit before tax from high-margin licensing business which generates massive royalties.

In fiscal 2014, the company generated nearly 50% of its global revenues ($26.5 billion) in China, with a large chunk of profit coming from higher-margin royalties earned from the company's licensing business. Therefore, a setback in China is likely to jeopardize its overall business model.

Nevertheless, the penalties that the company has to bear (including fine and royalty rate adjustment) are actually lesser than what the market was estimating. Many analysts opined that Qualcomm may have to pay over $1 billion coupled with forgoing a significant rate of LTE-TDD royalty.

Meanwhile, management stated that it will no longer challenge the NDRC’s decision and will cooperate with the Chinese government. This indicates that uncertainties about Qualcomm’s Chinese operations have come to an end.

Outlook Raised

Qualcomm has raised its total revenue and non-GAAP EPS guidance for fiscal 2015 on the heels of the NDRC settlement news. The current guidance for total revenues stands within the range of $26.3-$28 billion compared with the prior guidance of $26-$28 billion. The new non-GAAP EPS is projected within the range of $4.85-$5.05 against the prior guidance of $4.75-$5.05.

The Bottom Line

Qualcomm is the undisputed market leader for CDMA-based mobile microprocessors using baseband technology. The company’s chipsets are primarily used in high-end smartphones developed by Apple Inc. (AAPL), several handsets using Google Inc. (GOOGL) developed Android operating software and Microsoft Corp. (MSFT) developed Windows phones.

Recently, Samsung, the largest customer of Qualcomm decided not to use Qualcomm’s flagship Snapdragon 810 chipset in its upcoming Galaxy S6 smartphone. In addition, the U.S. Federal Trade Commission is investigating the company’s licensing business regarding fair and reasonable commitments, while the European Commission is examining rebates or financial incentives provided by the company related to its baseband chipsets.

At this juncture, settlement of issues in China, which currently offer significant growth opportunities, is a major achievement for Qualcomm.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

nach oben sind noch ein paar gaps offen welche geschlossen werden sollten.


MACD bullish cross
Volumen kommt rein

[waxweazle]

Antwort auf Beitrag Nr.: 49.034.567 von waxweazle am 10.02.15 23:08:11

yahooo

Hallo liebe Trader,

nachdem unser Apfel schön nach oben ausgebrochen ist sowie Ford.
habe ich jetzt eine neue Aktie Yahoo

Aber erst nochmals zu Ford.
EIn Gap ist noch offen mein Ziel erstmal wären die 17$.




Jetzt zu Yahoo.
Nachdem Alibaba schlechte Zahlen raus gebracht hatte schmierte Yahoo regelrecht ab.
Im Chart wurde ein Gap nach unten gerissen wie man es aktuell bei einigen CHart sehen kann.
z.b. bei Tesla wobei wir hier schon ein Gap schliessen konnten.

Nach dem wir zwischen dem Bereich von 42 und 43$ nun eine Boden gebildet haben ist heute die Aktie nach oben ausgebrochen und dürfte bald das Gap nach oben schliessen.

MACD bereit ein bullisches Kaufsignal zu generieren.
RSI konnte keine neuen Lows erreichen. Dreht aktuell nach oben weg
Volumen kommt rein.
Alles in allem sieht der chart sehr schön aus.



Beste Grüsse
waxweazle

[waxweazle]

Morphosys

Morphosys ist nach oben aus dem Abwärtstrend ausgebrochen.
Nur noch 78.5€ ist im weg zu neuen Jahreshochs

[waxweazle]

celgene vor charttechnischen Ausbruch

Hallo Trader,

Der Chart von celgene sieht sehr vielversprechend aus.

MACD bullischer Cross
RSI über 50
Aktie in der Nähe des 52 Wochenhoch

1. Ziel 130$





tolle News am Freitag:


REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant

Oral REVLIMID is approved for treatment until disease progression
Business Wire
Celgene International Sàrl February 20, 2015 3:30 AM






BOUDRY, Switzerland--(BUSINESS WIRE)--

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

The REVLIMID Marketing Authorisation has been updated to include this new indication in multiple myeloma, building upon the already approved indication of REVLIMID in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Multiple myeloma is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and suppression of the immune system.1 It is a rare but deadly disease: around 38,900 people were newly diagnosed with multiple myeloma in Europe in 2012, and 24,300 people died from the disease in the same year.2 On average, multiple myeloma is diagnosed in people 65–74 years of age,3 and the majority of newly diagnosed patients may not be eligible for more aggressive treatment options such as high-dose chemotherapy with stem cell transplant.4

Professor Thierry Facon, Services des Maladies du Sang, Hôpital Claude Huriez, and CHRU Lille, France, says: “Having a new treatment option now available for patients newly diagnosed with multiple myeloma is a real step forward. Treating patients continuously until disease progression is supported by several clinical studies, and will have an important impact on how we manage the disease over the long-term.”

“We are very pleased that physicians can now offer their patients a new and different treatment option,” said Tuomo Pätsi, President of Celgene in Europe, the Middle East and Africa (EMEA). “Multiple myeloma is rare, but it is devastating for those who have it, and it has a major impact on their friends and family too. We have seen significant progress in the treatment of the disease over the years, with an improvement of more than 50% in 5-year survival rates, but there continues to be a need for innovative new approaches to turn deadly diseases, like this one, into manageable, long-term, chronic conditions.”

The EC decision in newly diagnosed multiple myeloma was based on the results of two pivotal studies: MM-020 (also known as the FIRST trial) and MM-015.

The FIRST study, MM-020,5 was one of the largest phase III, multi-centre, open-label, randomised studies in patients newly diagnosed with multiple myeloma and not eligible for stem cell transplantation, including 1,623 patients. It compared lenalidomide plus dexamethasone administered in 28-day cycles until disease progression (Rd), with Rd for 72 weeks (18 cycles; Rd18) and melphalan-prednisone-thalidomide (MPT) for 72 weeks. Progression-free survival (PFS; study primary endpoint) was significantly improved in patients treated continuously with Rd, compared with those receiving MPT (primary comparison, p<0.0001) or Rd18 (p<0.0001). Median overall survival (OS) in patients receiving Rd continuous therapy was 58.9 months, vs. 48.5 months for patients treated with MPT (HR 0.75; 95% CI 0.62, 0.90), based on a March 3, 2014 interim OS analysis. The numbers of patients experiencing any grade 3 or 4 adverse event were similar in each group. The most frequent grade 3 or 4 adverse events were neutropenia, anaemia and infections.
MM-0155 was a multi-centre, randomised, double-blind, placebo-controlled phase III study of 459 patients that compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients ≥65 years or older with newly diagnosed multiple myeloma. Progression-free survival (PFS; study primary endpoint) was significantly improved in patients treated with MPR-R when compared with MPR and MP (p<0.001 for comparisons of MPR-R over MPR and MP). In the MM-015 study, overall survival was not significantly improved when compared across any treatment arm. During induction, the most frequent adverse events were hematologic (including neutropenia, thrombocytopenia, and anaemia). During the maintenance phase, the incidence of new or worsened grade 3 or 4 adverse events was low (0 to 6%).

The EC decision for the use of REVLIMID in newly diagnosed multiple myeloma in adult patients ineligible for transplantation follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) in December 2014. It is the second European Commission approval Celgene has received this year, following the approval of OTEZLA®, the first phosphodiesterase-4 (PDE-4) inhibitor for use in psoriasis and psoriatic arthritis, in January 2015. A CHMP positive opinion was also issued in January for use of the company’s oncology drug ABRAXANE®, in non-small cell lung cancer.

Celgene announced on 18 February 2015 that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma in the U.S.

About REVLIMID®

In the United States, REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma. In the European Union, REVLIMID is approved for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

REVLIMID is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in Europe for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

In addition, REVLIMID is approved in the United States for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. In Switzerland, REVLIMID is indicated for the treatment of patients with relapsed or refractory MCL after prior therapy that included bortezomib and chemotherapy/rituximab.

About Celgene

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly-owned subsidiary and International Headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com. Follow us on Twitter @Celgene, and on Pinterest and LinkedIn.


Beste Grüsse
waxweazle

[waxweazle]

Öl im Abwärtsttrend

Kurfirst Ziel 48.50 bis 48$

Langfristziel 38 - 30$

[waxweazle]

Twitter / GILD / Celg

Hallo liebe Trader,

Heute ist Twitter endlich über die 50$ nach oben ausgebrochen.
Twitter macht es Facebook nach.
Facebook ist vor 3 Handelstagen ausgebrochen und hat mehr als 10% bisher gemacht.

Twitter breakout über 50$
erstes Ziel 56$ letztes hoch bzw. Allzeithoch
MACD bullish cross
Volumen kommt rein.
Squeez?
Shortzahlen 32 Millione Aktien sind short das sind ca. 4,89%
Quelle:
http://shortsqueeze.com/?symbol=twtr&submit=Short+Quote%99




Gilead Sciences Incorporated

scheint fast am ende seiner langen Konsolidierung angekommen zu sein.
Wir haben ein schönes grosses Dreieck gebildet.
MACD Kaufsignal
wichtig wäre der Bruch des 200 Tagesdurchschnitt der ca. bei 102.43 liegt




Celgene habe ich wieder auf der Watchliste die letzten 2 Tage haben wir hier eine heftigen Abverkauf erlebt. Einstiegskurse drüften bald da sein.


Beste grüsse
waxweazle